MedTrace Logo

Performance Evaluation of ANI in Patients Under General Anesthesia With Remimazolam

NCT06432894 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-05-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether Analgesia Nociception Index (ANI) can effectively reduce the dose of opioid in patients who underwent general anesthesia using remimazolam.

Conditions

  • Pain Measurement

Interventions

COMBINATION_PRODUCT

Analgesia Nociception Index, remimazolam

The purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam. During this study, remimazolam infusion rate is determined by the pharmacopoeia. Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model. ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery.

Sponsors & Collaborators

  • Catholic Kwandong University

    lead OTHER

Principal Investigators

  • Young Joo · Ilsan Cha hospital

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-23
Primary Completion
2025-06-11
Completion
2025-06-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06432894 on ClinicalTrials.gov